search
Back to results

Efficacy/Safety of Cilnidipine Plus Valsartan Versus Valsartan in Patients With Hypertension

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 3
Locations
Korea, Republic of
Study Type
Interventional
Intervention
valsartan 160mg, cilnidipine 10mg, cilinidipine 5mg
Sponsored by
IlDong Pharmaceutical Co Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

20 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • essential hypertension patients whose blood pressure is not controlled before the study (sDBP≥90mmHg for drug-treated patients, sDBP≥95mmHg for drug-naive patients)

Exclusion Criteria:

  • sSBP≥80mmHg after 4weeks of valsartan 160mg treatment
  • has a history of hypersensitivity to dihydropyridines or angiotensin II receptor blockers

Sites / Locations

  • Seoul National University Bundang Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Active Comparator

Arm Label

Arm A

Arm B

Arm C

Arm Description

cilinidpine 10mg + valsartan 160mg

cilnidipine 5mg + valsartan 160mg

valsartan 160mg

Outcomes

Primary Outcome Measures

change from baseline in mean sDBP

Secondary Outcome Measures

change from baseline in mean sDBP
change from baseline in mean sSBP

Full Information

First Posted
May 20, 2014
Last Updated
June 11, 2018
Sponsor
IlDong Pharmaceutical Co Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT02145104
Brief Title
Efficacy/Safety of Cilnidipine Plus Valsartan Versus Valsartan in Patients With Hypertension
Official Title
Comparison of the Efficacy and Safety of Cilnidipine 10mg/Valsartan 160mg Combination Therapy, Cilnidipine 5mg/Valsartan 160mg Combination Therapy and Valsartan 160mg Monotherapy in Hypertensive Patients Inadequately Controlled With Valsartan 160mg Monotherapy: a Multicenter, Randomized, Double Blind Phase III Study
Study Type
Interventional

2. Study Status

Record Verification Date
June 2018
Overall Recruitment Status
Completed
Study Start Date
June 17, 2014 (Actual)
Primary Completion Date
June 7, 2016 (Actual)
Study Completion Date
September 29, 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
IlDong Pharmaceutical Co Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate of efficacy and safety of cilinidipine plus valsartan and valsartan alone in patients with essential hypertension inadequately controlled on valsartan monotherapy

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
286 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Arm A
Arm Type
Experimental
Arm Description
cilinidpine 10mg + valsartan 160mg
Arm Title
Arm B
Arm Type
Experimental
Arm Description
cilnidipine 5mg + valsartan 160mg
Arm Title
Arm C
Arm Type
Active Comparator
Arm Description
valsartan 160mg
Intervention Type
Drug
Intervention Name(s)
valsartan 160mg, cilnidipine 10mg, cilinidipine 5mg
Primary Outcome Measure Information:
Title
change from baseline in mean sDBP
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
change from baseline in mean sDBP
Time Frame
4 weeks
Title
change from baseline in mean sSBP
Time Frame
4, 8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: essential hypertension patients whose blood pressure is not controlled before the study (sDBP≥90mmHg for drug-treated patients, sDBP≥95mmHg for drug-naive patients) Exclusion Criteria: sSBP≥80mmHg after 4weeks of valsartan 160mg treatment has a history of hypersensitivity to dihydropyridines or angiotensin II receptor blockers
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dong Ju Choi, M.D., Ph.D.
Organizational Affiliation
Seoul National University Bundang Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Seoul National University Bundang Hospital
City
Seongnam-si
State/Province
Kyung-gi
Country
Korea, Republic of

12. IPD Sharing Statement

Learn more about this trial

Efficacy/Safety of Cilnidipine Plus Valsartan Versus Valsartan in Patients With Hypertension

We'll reach out to this number within 24 hrs